Treating chronic wound infections with genetically modified free flaps

Plastic and Reconstructive Surgery

Volumn 123, Issue 4, 2009, Pages 1157-1168

  Ghali, Shadi ^a   Bhatt, Kirit A ^a   Dempsey, Marlese P ^a   Jones, Deidre M ^a   Singh, Sunil ^a   Arabi, Shahram ^a   Butler, Peter E ^a   Gallo, Robert L ^a   Gurtner, Geoffrey C ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; RECOMBINANT VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; CATHETER INFECTION; CONTROLLED STUDY; DRUG SAFETY; EXPERIMENTAL MODEL; FOREIGN BODY INFECTION; FREE TISSUE GRAFT; FREE TISSUE GRAFT GENE THERAPY; GENE THERAPY; GENETIC TRANSDUCTION; GENETICALLY MODIFIED FREE TISSUE GRAFT; HUMAN; HUMAN CELL; INFECTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SUPERFICIAL INFERIOR EPIGASTRIC ARTERY FLAP; WOUND INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CATHELICIDINS; CHRONIC DISEASE; DRUG CARRIERS; GENETIC ENGINEERING; MALE; RATS; RATS, INBRED F344; SURGICAL FLAPS; WOUND INFECTION;

EID: 67749090995     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e31819f25a4     Document Type: Article

References (45)

1. Tallman P, Muscare E, Carson P, Eaglstein WH, Falanga V. Initial rate of healing predicts complete healing of venous ulcers. Arch Dermatol. 1997;133:1231-1234.
2. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004;364: 369-379.
3. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis. 2001;7:327-332.
4. Khare M, Keady D. Antimicrobial therapy of methicillin resistant Staphylococcus aureus infection. Expert Opin Pharmacother. 2003;4:165-177.
5. Stark W. The use of pedicled muscle flaps in the surgical treatment ofchronic osteomyelitis resulting from compound fractures. J Bone Joint Surg (Am.) 1946;28:343-350.
6. Ger R, Efron G. New operative approach in the treatment of chronic osteomyelitis of the tibial diaphysis: A preliminary report. Clin Orthop Relat Res. 1970;70:165-169.
7. Byrd HS, Cierny G III, Tebbetts JB. The management of open tibial fractures with associated soft-tissue loss: External pin fixation with early flap coverage. Plast Reconstr Surg. 1981;68:73-82.
8. Byrd HS, Spicer TE, Cierney G III. Management of open tibial fractures. Plast Reconstr Surg. 1985;76:719-730.
9. Smith IM, Austin OM, Batchelor AG. The treatment of chronic osteomyelitis: A 10 year audit. J Plast Reconstr Aesthet Surg. 2006;59:11-15.
10. A report by the British Orthopaedic Association/British Association of Plastic Surgeons Working Party on the management of open tibial fractures. September 1997. Br J Plast Surg. 1997;50:570-583.
11. Godina M. Early microsurgical reconstruction of complex trauma of the extremities. Plast Reconstr Surg. 1986;78:285-292.
12. Gonzalez MH, Tarandy DI, Troy D, Phillips D, Weinzweig N. Free tissue coverage of chronic traumatic wounds of the lower leg. Plast Reconstr Surg. 2002;109:592-600.
13. Yazar S, Lin CH, Lin YT, Ulusal AE, Wei FC. Outcome comparison between free muscle and free fasciocutaneous flaps for reconstruction of distal third and ankle traumatic open tibial fractures. Plast Reconstr Surg. 2006:117:2468-2475; discussion 2476-2477.
14. Ghali S, Dempsey MP, Jones DM, Grogan RH, Butler PE, Gurtner GC. Plastic surgical delivery systems for targeted gene therapy. Ann Plast Surg. 2008;60:323-332.
15. Michaels JV, Dobryansky M, Galiano RD, et al. Ex vivo transduction of microvascular free flaps for localized peptide delivery. Ann Plast Surg. 2004;52:581-584.
16. Michaels JV, Levine JP, Hazen A, et al. Biologic brachytherapy: Ex vivo transduction of microvascular beds for efficient, targeted gene therapy. Plast Reconstr Surg. 2006;118:54-65; discussion 66-68.
17. Dempsey MP, Hamou C, V JM, et al. Using genetically modified microvascular free flaps to deliver local cancer immunotherapy with minimal systemic toxicity. Plast Reconstr Surg. 2008;121:1541-1553.
18. Izadpanah A, Gallo RL. Antimicrobial peptides. J Am Acad Dermatol. 2005;52:381-390.
19. Nizet V, Gallo RL. Cathelicidins and innate defense against invasive bacterial infection. Scand J Infect Dis. 2003;35:670-676.
20. Bals R, Weiner DJ, Moscioni AD, Meegalla RL, Wilson JM. Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun. 1999;67:6084-6089.
21. Strauch B, Murray DE. Transfer of composite graft with immediate suture anastomosis of its vascular pedicle measuring less than 1 mm in external diameter using microsur-gical techniques. Plast Reconstr Surg. 1967;40:325-329.
22. Kadurugamuwa JL, Sin L, Albert E, et al. Direct continuous method for monitoring biofilm infection in a mouse model. Infect Immun. 2003;71:882-890.
23. Dorschner RA, Lopez-Garcia B, Peschel A, et al. The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides. FASEB J. 2006;20:35-42.
24. Zaiou M, Gallo RL. Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med. 2002;80:549-561.
25. Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother. 1998;42:2206-2214.
26. Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochim Biophys Acta. 2002;1575:1-14.
27. Kerrigan CL, Daniel RK. Critical ischemia time and the failing skin flap. Plast Reconstr Surg. 1982;69:986-989.
28. Zelt RG, Olding M, Kerrigan CL, Daniel RK Primary and secondary critical ischemia times of myocutaneous flaps. Plast Reconstr Surg. 1986;78:498-503.
29. Eckert P, Schnackerz K Ischemic tolerance of human skeletal muscle. Ann Plast Surg. 1991;26:77-84.
30. Siemionow M, Arslan E. Ischemia/reperfusion injury: A review in relation to free tissue transfers. Microsurgery 2004;24:468-475.
31. Contag CH, Contag PR Mullins JI, Spilman SD, Stevenson DK Benaron DA. Photonic detection of bacterial pathogens in living hosts. Mol Microbiol. 1995;18:593-603.
32. Contag PR Olomu IN, Stevenson DK Contag CH. Bioluminescent indicators in living mammals. Nat Med. 1998;4:245-247.
33. Bals R WangX, Zasloff M, WilsonJM. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 1998:95:9541-9546.
34. Nagaoka I, Hirota S, Niyonsaba F, et al. Augmentation of the lipopolysaccharide-neutralizing activities of human cathelicidin CAP18/LL-37-derived antimicrobial peptides by replacement with hydrophobic and cationic amino acid residues. Clin Diagn Lab Immunol. 2002;9:972-982.
35. Nagaoka I, Hirota S, Niyonsaba F, et al. Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14( + ) cells. J Immunol. 2001;167:3329-3338.
36. Kirikae T, Hirata M, Yamasu H, et al. Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP18)derived peptide against murine endotoxemia. Infect Immun. 1998;66:1861-1868.
37. De Yang, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000;192:1069-1074.
38. Di Nardo A, Vitiello A, Gallo RL. Cutting edge: Mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol. 2003;170: 2274-2278.
39. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003;111:1665-1672.
40. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 1992;359:843-845.
41. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endo-thelial growth factor. J Cell Sci. 1995;108:2369-2379.
42. Greelish JP, Su LT, Lankford EB, et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med. 1999;5:439-443.
43. Gregorevic P, Blankinship MJ, Allen JM, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med. 2004;10:828-834.
44. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999;286:2244-2245.
45. Somia N, Verma IM. Gene therapy: Trials and tribulations. Nat Rev Genet. 2000;1:91-99.